Kyverna Therapeutics, Inc. (KYTX)
(Delayed Data from NSDQ)
$7.38 USD
+0.04 (0.54%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $7.32 -0.06 (-0.81%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Kyverna Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -60.37 | -28.89 | NA | NA | NA |
Depreciation/Amortization & Depletion | 1.71 | 1.05 | NA | NA | NA |
Net Change from Assets/Liabilities | 3.42 | -10.33 | NA | NA | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | NA | NA | NA |
Other Operating Activities | 2.83 | 2.06 | NA | NA | NA |
Net Cash From Operating Activities | -52.41 | -36.11 | NA | NA | NA |
Property & Equipment | -0.62 | -0.77 | NA | NA | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | NA | NA | NA |
Investments | -8.16 | -13.33 | NA | NA | NA |
Other Investing Activities | 0.00 | 0.00 | NA | NA | NA |
Net Cash from Investing Activities | -8.79 | -14.10 | NA | NA | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.65 | 0.18 | NA | NA | NA |
Issuance (Repayment) of Debt | 59.12 | 11.71 | NA | NA | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | NA | NA | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | NA | NA | NA |
Other Financing Activities | -1.65 | 0.00 | NA | NA | NA |
Net Cash from Financing Activities | 58.12 | 11.88 | NA | NA | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | NA | NA | NA |
Net Change In Cash & Equivalents | -3.08 | -38.33 | NA | NA | NA |
Cash at Beginning of Period | 38.29 | 76.62 | NA | NA | NA |
Cash at End of Period | 35.21 | 38.29 | NA | NA | NA |
Diluted Net EPS | -89.61 | -63.43 | NA | NA | NA |
Fiscal Year End for Kyverna Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -55.50 | -26.69 | -60.37 | NA | -24.23 |
Depreciation/Amortization & Depletion | 1.01 | 0.48 | 1.71 | NA | 0.81 |
Net Change from Assets/Liabilities | 2.57 | -1.84 | 3.42 | NA | -0.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Operating Activities | 2.21 | 2.52 | 2.83 | NA | 1.67 |
Net Cash From Operating Activities | -49.70 | -25.53 | -52.41 | NA | -22.72 |
Property & Equipment | -1.57 | -0.54 | -0.62 | NA | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Investments | -189.23 | -122.34 | -8.16 | NA | 13.68 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Cash from Investing Activities | -190.80 | -122.88 | -8.79 | NA | 13.65 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 341.31 | 341.24 | 0.65 | NA | 0.06 |
Issuance (Repayment) of Debt | -0.47 | -0.23 | 59.12 | NA | 24.70 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Other Financing Activities | -3.36 | -2.96 | -1.65 | NA | 0.00 |
Net Cash from Financing Activities | 337.48 | 338.05 | 58.12 | NA | 24.76 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | NA | 0.00 |
Net Change In Cash & Equivalents | 96.98 | 189.65 | -3.08 | NA | 15.70 |
Cash at Beginning of Period | 35.21 | 35.21 | 38.29 | NA | 38.29 |
Cash at End of Period | 132.19 | 224.86 | 35.21 | NA | 53.99 |
Diluted Net EPS | -0.67 | -1.12 | NA | NA | NA |